Please assess the completion status of the following clinical trial:

Trial Title: A Study of Local Effect and Safety of a Single PPC-5650 Dose on Reflux Pain During Pain Stimulation in the Esophagus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent before any study specific procedures~* Able to read and understand Danish.~* Healthy i.e. no history of chronic or recurrent pain rewarding diseases~* Able to co-operate and tolerate the experimental procedures (as assessed in the training visit)~* No over the counter medication 24h before the three visits~* No medications in the study period~* BMI 18.5-35.0~* Caucasian~* No symptoms of Gastroesophageal reflux disease~* All men must use a safe method of contraception during the study period~Exclusion Criteria:~* Any clinically relevant abnormal values from the laboratory tests on hematology, clinical chemistry, and/or urine analyses, as judged by the investigator.~* Participation in any other clinical trial within three months prior to the training day.~* Alcohol or drug abuse.~* Mental illnesses~* Allergic to the active ingredient in the investigational medicinal product

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Placebo solution (Type: PLACEBO_COMPARATOR): A 100 ml placebo solution will be administered through an esophageal probe. 100 ml will be administered as an infusion with a rate of 7ml/min. Healthy volunteers will be treated with placebo in one out of three visit days.
- PPC-5650 (Type: ACTIVE_COMPARATOR): PPC-5650 is a asic-sensing ion channel-1a antagonist that can block the acid-sensing ion channels, leading to a reduction in the pain signal under up-regulated conditions. A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered through an esophageal probe to assess local effects. 100 ml will be administered as an infusion with a rate of 7ml/min. Healthy volunteers will be treated with PPC-5650 in one out of three visit days.

Based on this trial design, predict the completion outcome and termination type (if applicable).